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Abstract Neuroendocrine tumors of the gastroentero-
pancreatic system are defined by their endocrine phenotype
and share many histopathological and clinical features.
However, the fact that the hormone production of tumors
depends on their site of origin, that the tumors differ in their
biology, and that the association with familial syndromes is
nonrandom suggests heterogeneity. It is therefore conceiv-
able that the gastroenteropancreatic neuroendocrine tumors
also differ in their molecular profile. This review summa-
rizes and discusses the available data in this field.
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Introduction
Well-differentiated gastroenteropancreatic neuroendocrine
tumors (GEP-NETs) are defined by their capacity to express
neuroendocrine markers and to produce and/or secrete
peptide hormones, biogenic amines, and tachykinins.
Pancreatic endocrine tumors (PETs) may arise in
association with a multiple endocrine neoplasia type 1
(MEN1), von Hippel–Lindau (VHL), or rarely neuro-
fibromatosis type 1 (NF1) or tuberous sclerosis (TSC)
syndrome, and the genes responsible for these familial
diseases have been described. However, about 90% of PETs
and the vast majority of gastrointestinal endocrine tumors
are sporadic, and still little is known about the molecular
basis of GEP-NETs.
Activation of oncogenes is rare in sporadic PETs [21, 23,
29]. Activating mutations of β-catenin were described in
37% of gastrointestinal NETs [14] but were not detected in
exon 3 in a series of 15 PETs (own unpublished data).
Mutations of TP53, K-ras, p16, DPC4, or DCC, which are
found frequently in gastrointestinal adenocarcinomas, were
not identified in GEP-NETs [22, 28–30, 33, 41]. CGH and
loss of heterozygosity (LOH) data point toward the
involvement of other chromosomal regions. In this article,
we review the genetic alterations that have been identified
in GEP-NETs, using ribonucleic acid expression arrays,
comparative genomic hybridization (CGH), LOH, and gene
mutation analysis.
Pancreatic endocrine tumors
Genome-wide analysis: RNA expression arrays
With the development of high-throughput techniques,
analysis of the expression of thousands of genes in a given
tumor has become possible. The use of RNA expression
arrays can further our understanding of tumor classification.
It can also provide signatures (gene lists classifying tumors
into distinct groups) that may have prognostic implications.
While this technique has led to new (sub)classifications in
other tumors (lymphoma, breast cancer), only limited
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results have been published for GEP-NETs. For these
tumors, class comparison studies rather than class predic-
tion or class discovery studies have been performed. Class
comparison studies analyze the gene expression in groups
of specimens defined by other methods such as histopath-
ological, immunohistochemical, or clinical features. This
analysis identifies genes that are differentially expressed
between the different tumor types.
As biological behavior is difficult to predict in PETs, the
largest published RNA expression array study on PETs
compared metastasized with nonmetastasized PETs [10].
By comparing 12 localized to 12 metastasized PETs, the
signature of 51 genes that are downregulated in malignant
PETs and 72 that are upregulated in malignant PETs
emerged. These genes were involved in pathways related
to (1) angiogenesis and remodeling, (2) signal transduction
through tyrosine kinases, (3) calcium-dependant cell sig-
naling, and (4) response to therapeutic drugs.
A different approach was taken in the study by Maitra et
al. [31]. In this study, transcripts from eight well-differen-
tiated PETs were compared with transcripts of three
enriched pancreatic islet cell samples with 80–90% purity.
Their aim was to identify potential therapeutic targets and
novel tumor markers in PETs. None of the patients had an
associated endocrine hypersecretion syndrome; therefore,
all eight tumors were nonfunctioning tumors. One of the
tumors revealed somatostatin expression. Two tumors had
lymph node metastases and measured 2 cm or less in
diameter. The authors described 66 transcripts with three-
fold overexpression in PETs and 119 underexpressed
transcripts. The underexpressed genes included cell cycle
checkpoint proteins (p21, MICT) and genes involving
deoxyribonucleic acid (DNA) damage repair and genomic
stability (O-methylguanine DNA-methyltransferase and
GADD 45). The number of differentially expressed genes
was rather low in this study. One reason might be the
applied high threshold of “threefold change” and the other,
the selection of tumor types. The group of nonfunctioning
tumors might be a potpourri of PETs expressing hormones
at low levels. Furthermore, the study included many large
tumors that may have accumulated extensive genetic
changes, at least as expected from CGH studies. While
the aim of the study to detect therapeutic markers is not yet
accomplished, these gene lists will provide useful candidate
genes for further detailed analyses.
In a second study, this group extended their analysis to
the differential expression of genes in well-differentiated
metastatic and nonmetastatic PETs [18]. The expression
profiles of seven metastatic PETs were compared with the
profiles of five nonmetastatic PETs. Sixty-five transcripts
were overexpressed, and 57 transcripts were underex-
pressed in metastatic PETs compared to nonmetastatic
ones. In this attempt to find a progression model from
nonmetastatic to metastatic PETs, the gain of function of
genes involved in growth regulation, cholesterol homeosta-
sis, osmotic regulation, and hypoxia-inducible factors were
described. Underexpression of genes involved in cell cycle
regulation, developmental regulation, and DNA damage
repair was described. Theses two studies showed a
continuum of upregulation of IGFBP3 from normal islets
to nonmetastasizing PETs and to metastasizing PETs.
Malignant tumors showed an overall pathway activation
of the insulin-like growth factor-signaling cascade, but the
underlying mechanisms still have to be elucidated.
The rate of differentially expressed genes described was
dramatically higher in the study by Carpuso et al. [7].
Comparing RNA extracts of 13 nonfunctioning PET (NF-
PET) samples (eight primaries and five metastases) to
extracts of four isolated islet preparations, they found 990
differentially expressed individual genes. Only 20 of the
reported 667 upregulated genes were also described in the
aforementioned similar studies (fibronectin [31], elongation
of very long fatty acid-like 2 [6], coagulation factor V [18],
and mitogen activated protein kinase 3 [17]). The authors
described a striking similarity between primary malignant
PETs and their metastases concerning their genetic profile:
Metastases clustered with their corresponding primary
tumors in most instances. This is evidence that the
metastatic potential is acquired in an early stage of tumor
transformation because cells of the primary tumor already
carry the metastatic signatures.
Shalev et al. [42] compared isolated islets with and
without glucose challenge. Fourteen genes were upregu-
lated by glucose in all three independent experiments, and
only six genes were downregulated. The authors were able
to show that upregulation of transforming growth factor β
(TGFβ) signaling was induced by glucose. As TGFβ is
also known to be involved in differentiation, this raises the
intriguing possibility that there might be crosstalk between
glucose metabolism, development, and the immune system
in human pancreatic islets.
The research on PETs using expression array techniques
has only recently started, and it is anticipated that
significant results will be published in the years to come.
Future studies comprising larger numbers of well-charac-
terized tumors are needed, and class prediction studies
rather than simple class confirmation studies will allow the
identification of subsets of endocrine tumors that are caused
by different genetic changes and that might therefore
respond to targeted therapies.
Genome-wide analysis: CGH studies
Four conventional CGH studies included a total of 102
PETs. These studies indicate that chromosomal losses occur
slightly more frequently than gains, whereas amplifications
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are uncommon [45–47, 58]. Genetic alterations seem to
accumulate during tumor progression: The total number of
genomic changes per tumor appears to be associated with
both the tumor volume and the stage of the disease [46]
Thus, large and/or malignant tumors and especially metas-
tases harbor a larger number of genetic alterations than
small and clinically benign neoplasms [46, 58] These
findings point toward a tumor suppressor pathway and
chromosomal instability as important mechanisms associ-
ated with malignancy in PET. These data have recently
been confirmed for insulinomas in a large array CGH
analysis studying 30 insulinomas. At least 20 chromosomal
alterations and six telomeric losses were the best predictors
of malignancy [26]. The alterations described are not
randomly distributed on chromosomes but are particularly
common in distinct chromosomal regions. Gains are
common on 4pq (17% of the tumors), 5q (25%), 7pq
(41%), 9q (28%), 12q (23%), 14q (32%), 17pq (31%), and
20q (27%), whereas genomic losses frequently occur on 1p
(21%), 3p (19%), 6q (28%), 10pq (14%), 11q (30%), Y
(31%), and X (31%) [45–47, 58]. Furthermore, genomic
alterations in some chromosomal regions appear to be
associated with the stage of the disease and, additionally,
with particular tumor types. For example, losses of
chromosome 1 and 11q as well as gains of 9q appear to
be early events in the development of PETs because they
are already present in many small tumors (<2 cm) [46].
Some defects, e.g., losses of 3p, 6pq, and 10pq and gains of
5q, 12q, 18q, and 20q, were shown to be associated with
malignant behavior [2, 3, 46], whereas gains of chromo-
somes 4 and 7 in the presence of losses of 21q prevailed in
metastases [58].
Insulinomas exhibit a lower number of genomic alter-
ations than other PETs [45–47, 58]. Insulinomas often have
chromosomal aberrations consisting of a gain of 9q32 and
loss of 22q13.1, which may occur in the same tumor and
appear to be early genetic events in these tumors [25].
Losses of 3p and 6q associated with malignancy are
particularly rare in insulinomas [2, 3]. Malignant insulin-
omas, in contrast, harbor a large number of chromosomal
alterations similar to that seen in other types of malignant
PET [26].
In pancreatic gastrinomas, only limited chromosomal
imbalances are encountered: Losses at 3p and 18q21 occur
in approximately 33 and 22% of cases, respectively [46, 47,
58]. It is interesting to know that 18q losses are also
common in gastrointestinal NETs, indicating that NETs and
pancreatic gastrinomas might be related. NF-PETs in
general harbor higher numbers of chromosomal gains and
losses than functioning tumors. These genetic aberrations
occur in chromosomal loci frequently involved in malig-
nant tumors [58]. Gains of chromosome 4 and losses of 6q
appear to be early events because they are already
detectable in 40 and 50% of tumors with a diameter of
less than 2 cm [46].
Loss of heterozygosity and mutation analysis
Analyses of LOH using polymerase chain reaction micro-
satellite markers identify the same chromosomal regions as
those described by CGH. The rate of alterations detected by
microsatellite analysis is, however, approximately twice
that of the allelic losses detected by CGH. In the regions
3p23, 6q22, 9p, 11q13, 18q21, and 22q12.1, the differences
are even more pronounced, indicating that small deletions
that are not detectable by CGH may be involved [2, 3, 16,
19, 20, 32, 33, 37, 41, 59]. These regions displaying losses
might harbor tumor suppressor genes involved in the
initiation and progression of PETs. However, only a few
candidate genes have been thoroughly investigated, and
many genes remain to be tested.
The most important candidate gene is the MEN1 gene.
We know that almost all PETs in MEN1 patients, including
microadenomas show allelic loss of the wild-type allele [19,
34, 51]. However, somatic mutations of the MEN1 gene
located on 11q13 are detectable in only 21% (33 of 155) of
sporadic PETs [11, 16, 32, 43, 53, 59]. When PETs are
stratified according to the hormonal syndrome they cause,
the rate of MEN1 mutations varies considerably between
the subgroups. Thus, MEN1 mutations are only detected in
7.7% (5 of 65) of insulinomas and 8% (2 of 26) of NF-
PETs. In contrast, gastrinomas, glucagonomas, and VIPo-
mas show a higher mutation rate of 37, 67, and 44%,
respectively [11, 15, 16, 32, 43, 53, 56, 59].
In contrast to the low rate of 21% MEN1 mutations, 68%
of all PETs exhibit losses at 11q13 and/or of more distal
parts of the long arm of chromosome 11, indicating that
there might be a haploinsufficiency of the MEN1 gene or
that the other allele might be inactivated by epigenetic
mechanisms. CpG island methylation in the MEN1 pro-
moter, however, was not identified [8]. Another explanation
for this high rate of LOH is that further, yet unknown tumor
suppressor genes in this region might be involved [11, 12,
16, 32, 43, 53, 59]. An important role of the SDHD gene
(one of the candidate genes on 11q23) in the pathogenesis
of PETs and other endocrine tumors has recently been
excluded [35].
Another familial syndrome associated with PETs is
VHL. Intriguingly, somatic VHL gene mutations have been
detected in only 1 of 22 sporadic PETs, despite the high
LOH rate on 3p25, indicating that the gene is less
frequently involved than expected [9, 32]. NF1 and TSC
patients may also develop PETs. However, the role of the
NF1 and TSC1/2 genes in sporadic tumors has not been
examined so far.
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Several other tumor suppressor genes or oncogenes
have been examined in PETs. These genes include p16,
PTEN, k-RAS, and p53, which are only occasionally
mutated and therefore seem to be of minor importance [5,
26, 33, 36, 41, 54]. RET, hZAC, BRAF, and SMAD3 have
been excluded as candidate genes [28, 38, 44, 49].
Furthermore, we recently were unable to detect any somatic
mutation of the HRPT2 gene on 1q25 in 25 examined PETs
(unpublished observations).
The role of DPC4/Smad4 in sporadic PETs also seems to
be of minor importance. The high mutation rates described
by one group [4] could not be confirmed by subsequent
studies on a larger number of tumors by several other
groups [30, 33, 37]. The classical tumor suppressor genes
PTEN, p53, and DPC4 are only rarely mutated, mostly in
malignant tumors, and alterations of these genes therefore
most likely represent late events in PET progression.
Gastrointestinal endocrine tumors
Genome-wide analysis
Knowledge about the genetic background of sporadic
gastrointestinal NETs is even sparser than that of PETs.
No results of RNA expression array analyses have been
reported so far. Only three studies using CGH [50, 57] or
131 microsatellite LOH markers [30] examined genome-
wide allelic imbalances in gastrointestinal NETs. The
average number (2.9) of genomic changes was lower in
gastrointestinal NETs than in PETs, and there was no clear
correlation between the number of aberrations and tumor
stage [57]. Furthermore, the number of different chromo-
somes involved was low, genetic alterations apparently
being concentrated on chromosome 18. The study by Zhao
et al. [57] described losses of the entire chromosome 18 or
of its long arm in 38% of gastrointestinal NETs, whereas
others reported these losses to occur in 50 [50] or even in
88% of tumors [30]. The high percentage reported by
Lollgen et al. [30] is based on microsatellite LOH analysis,
in which small deletions are detected with a higher
sensitivity than obtained by CGH. The loss of chromosome
18 in gastrointestinal NETs is strong evidence that
important candidate tumor suppressor genes are located on
this chromosome. Most of these genes are most likely
located on the long arm of chromosome 18.
In the three aforementioned studies [30, 50, 57],
significant genetic differences between bronchial NETs,
gastrointestinal NETs, and PETs were described, suggesting
a different genetic background for these tumor groups. For
example, losses of chromosome 18 are rare in bronchial
tumors and PETs, whereas losses of chromosome 11 are
common [57]. Furthermore, losses of 9p, which are
detectable in 50% of gastrointestinal NETs, are rare in
PETs, which in contrast more frequently exhibit gains of
17q and losses of 11q.37.
LOH and mutation analysis
The candidate genes DPC4, DCC, and Smad2 were
investigated because of the frequent allelic loss on 18q
(88% of gastrointestinal NETs) [30] but were found to be
unaltered in a small series of tumors. In the study by
Lollgen et al. [30], all eight examined gastrointestinal NETs
contained a wild-type C-terminal DPC4 sequence encoded
by exon 8–11 and conserved DPC4 protein expression as
demonstrated by immunohistochemistry [30]. In our study
on 21 gastrointestinal NETs, DPC4 and DCC mutations
were not detected using single-strand conformation poly-
morphism analysis (unpublished observations). Therefore,
other possible tumor suppressor genes located on chromo-
some 18 remain to be investigated.
Patients suffering from MEN1 often develop NETs; most
of which are localized in the duodenum and the stomach.
Allelic loss of the corresponding chromosomal arm 11q has
been detected in these types of endocrine tumors associated
with the MEN1 syndrome. LOH of 11q is also consistently
found in a subset of sporadic endocrine tumors of various
localizations, although the observed LOH frequency varies.
Although it is very low in the ileum (14% of tumors), it
amounts to 25% in the ascending colon, to 30% in the
pancreas and stomach, to approximately 50% in NETs of
the descending colon and rectum, and to 60% in the
duodenum [13, 15, 16, 24, 30, 56].
Enterochromaffin-like (ECL)-cell gastric NETs associat-
ed with chronic atrophic gastritis (type I gastric NETs) arise
in association with ECL-cell hyperplasia and are often
multiple [40]. LOH of 11q was present in only one of six
such tumors examined. In the setting of the MEN1
syndrome, MEN1 LOH, however, occurred in 15 of 20
type II gastric NETs arising in patients with a Zollinger–
Ellison syndrome because of duodenal gastrinomas [13].
Two examined sporadic gastric NETs (type III gastric
NETs) exhibited allelic loss of 11q microsatellite markers
[16].
With the exception of sporadic gastrinomas, only few
gastrointestinal NETs have been examined for MEN1 gene
mutations. The MEN1 mutation rate in sporadic gastrin-
omas was high (31%). This ratio was comparable to that
found in PETs [15]. This is not surprising, as duodenal
gastrinomas and PETs are both classical MEN1-associated
tumors. Somatic MEN1 mutations have also been detected
in a small subset of NETs of the ileum (one of four tumors
examined) and colon, indicating that these mutations are
not restricted to foregut NETs but may also occur rarely in
midgut and hindgut tumors [16].
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The tumor suppressor genes p16 and TP53 have also
been investigated in NETs. Like in PETs, no mutations of
the p16 tumor suppressor gene have been identified.
However, a 5′ CpG island of the p16 gene promoter was
methylated in 52% of gastrinomas [41] and in other types
of gastrointestinal NET [8]. Furthermore, methylation of
p16 was significantly more frequent in NETs than in PETs
and thus represents an additional molecular difference
between the two tumor groups [8]. It is interesting to know
that a recent study also described higher rates of promoter
methylation of the APC, MEN1, HIC1, and RASSF1a genes
in gastrointestinal NETs [1]. This is good evidence that
CpG island methylator phenotype (CIMP) is frequent in
gastrointestinal NETs. Microsatellite instability does not
occur in PETs or gastrointestinal NETs, and the hMLH1
gene is not methylated [1, 27]. The high rate of RASSF1a
promoter methylation might explain the frequent expression
of extracellular signaling-related kinase (ERK) 1/2, an
important downstream point of convergence in the ras-
RAF-mitogen-activated protein ERK pathway [49].
Accumulation of the TP53 protein was detected by
immunohistochemistry in only one duodenal gastrinoma with
an identified 17p loss and thus seems to be a rare event in
NETs [50]. However, in 25% of goblet cell carcinoids of the
appendix, TP53 mutations were reported to occur [39]. The
most frequently reported mutated gene in gastrointestinal
NETs isβ-catenin. Mutations in exon 3 of this gene protecting
the corresponding protein from phosphorylation and degrada-
tion have been reported in 38% (27 of 72) of NETs [14].This
leads to cytoplasmic and nuclear accumulation of β-catenin
(demonstrated by immunohistochemistry) in 79% of these
tumors, indicating other, yet unknown, mechanisms of
accumulation of this protein. Only one of these 72 tumors
(1.4%) displayed a mutation of the APC gene. However, the
rate of gastrointestinal NETs with nuclear translocation of β-
catenin was only 30% in a later study, and exon 3 mutations
were absent [48]. The reported overexpression of cyclin D1
and c-myc [52] may be a downstream effect of the alterations
of the Wnt signaling pathway. Other examined oncogenes
appear to be of minor importance. Hardly any tumors show
amplifications of the HER2 gene [50], and in contrast to
gastrointestinal adenocarcinomas, no K-Ras mutations were
detected in gastrointestinal NETs [55] (Table 1).
Conclusion and perspective
The available molecular data indicate that the tumorigenesis
of well-differentiated GEP-NETs differs from that of their
nonendocrine counterparts. This is supported by results of
CGH, LOH, and mutation analyses that point to different
genetic pathways leading to the formation of GEP-NETs. In
addition, subgroups of GEP-NETs appear to have special
genetic pathways. PETs (especially NF-PETs, glucagon-
omas, and VIPomas) show a higher average number of
chromosomal aberrations and allelic losses than gastroin-
testinal NETs. RNA expression analysis describes deregu-
lation of cell cycle checkpoint proteins as well as genes
Table 1 Genetic changes frequently found in GEP-NETs
Gene(s) Involvement
Frequent Rare Absent
Genes characterizing endocrine tumor syndromes men1 PET, D G, I
vhl PET
nf-1
tsc-1/2
hrpt-2 PET
SDHx PET, gasNET
Wnt signaling pathway b-catenin gasNET PET
APC gasNET
TGFbeta signaling pathway TGFbR2 PET, gasNET
Smad4 PET
Smad3 PET
Common tumor suppressor genes/oncogenes DCC PET, gasNET
p53 PET, gasNET
PTEN PET
K-Ras PET, gasNET
Mechanisms of tumorigenesis CIMP pathway gasNET PET
Chromosomal instability PET gasNET
MSI PET, gasNET
GEP-NET Gastroenteropancreatic neuroendocrine tumor, PET pancreatic endocrine tumor, D duodenal endocrine tumor, I ileal endocrine tumor,
gasNET gastrointestinal neuroendocrine tumor, CIMP CpG island methylator phenotype, MSI microsatellite instability
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involved in DNA damage repair and genomic stability. It
will be an important task to find the underlying cause of
chromosomal instability (that is particularly observed in
malignant PETs and less pronounced in benign insulinomas
and duodenal gastrinomas) because this might identify new
therapeutic targets. Furthermore, some chromosomal loci
are preferentially altered in NETs: Gastrointestinal NETs
frequently show 18q losses, while PETs commonly exhibit
11q losses involving the MEN1 gene. Because PETs, in
particular insulinomas and NF-PETs, only rarely harbor
somatic MEN1 mutations and there is no known tumor
suppressor gene on 18q, the 11q and 18q losses may suggest
that potential new tumor suppressor genes are located in both
chromosomal areas. MEN1 gene deletions are very rare in
ileal and appendiceal NET, as are somatic MEN1 mutations.
Additional differences between PETs and gastrointestinal
NETs concern the tumor suppressor gene p16 and β-catenin
as well as the CIMP pathway (Table 1, bottom). p16 is more
frequently methylated and β-catenin more often mutated in
gastrointestinal NETs than in PETs, and gastrointestinal NETs
more often exhibit alterations associated with the CIMP
pathway, whereas advanced PETs frequently reveal chromo-
somal instability. Taken together, these data may explain why
GEP-NETs, depending on their site of origin and phenotype,
differ in their biological behavior and, in addition, stress the
importance of classifying endocrine tumors according to their
localization and hormone production.
Current results combined with those obtained by new
technologies, such as DNA and RNA expression and tissue
arrays, will probably result in a more clear-cut picture of the
molecular background of the oncogenesis and progression
of GEP-NETs. These findings, in turn, might subsequently
lead to precisely tailored diagnostic and therapeutic
strategies in the near future.
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